Goldman Sachs Analysts Weigh in on Healthcare Companies: Merck & Company, Moderna, and Akari Therapeutics

Analysts have weighed in on several healthcare companies, including Merck & Company (MRK), Moderna (MRNA), and Akari Therapeutics (AKTX).

According to Goldman Sachs analyst Asad Haider, Merck & Company has a Strong Buy consensus with an average price target of $138.60, representing a -5.7% downside from its current share price of $150.15.

Haider maintained a Buy rating on Merck & Company with a price target of $140.00 and has a 5-star analyst ranking with an average return of 25.8% and a 89.1% success rate.

In contrast, Goldman Sachs analyst Salveen Richter maintained a Hold rating on Moderna with a price target of $120.00, despite the company's shares closing last Wednesday at $151.10, close to its 52-week high of $170.47.

Richter has a 5-star analyst ranking with an average return of 13.2% and a 51.6% success rate.